MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.49 (-1.54%)
As of 2:26PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close32.10
Bid31.650 x 1100
Ask31.640 x 1400
Day's Range31.52 - 32.22
52 Week Range26.03 - 44.18
Avg. Volume4,421,160
Market Cap16.297B
Beta (3Y Monthly)1.69
PE Ratio (TTM)30.16
EPS (TTM)1.048
Earnings DateFeb 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est41.67
Trade prices are not sourced from all markets
  • Reutersyesterday

    U.S. top court rejects Maryland bid to revive drug price-gouging law

    The U.S. Supreme Court on Tuesday rejected Maryland's bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs. The justices declined to take up Maryland's appeal of a 2018 federal appeals court ruling that struck down the state's law, That ruling held that Maryland had regulated wholesale pricing by the companies in violation of the U.S. Constitution's bar on state-level regulation of interstate commerce.

  • Reutersyesterday

    Teva expects sales injection from U.S. EpiPen market

    Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to claim about 25 percent of the U.S. market by the end of the year, CEO Kare Schultz said on Tuesday, as the company closes in on a return to growth in 2020. Wall Street has viewed the EpiPen rival as a welcome profit-booster for Teva as it contends with declining U.S. margins for its older generic medicines, competition for multiple sclerosis treatment Copaxone and costly acquisitions.

  • What Analysts Are Recommending for Teva Pharmaceutical This Month
    Market Realist2 days ago

    What Analysts Are Recommending for Teva Pharmaceutical This Month

    Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower

  • Moody's5 days ago

    Mylan Inc. -- Moody's announces completion of a periodic review of ratings of Mylan N.V.

    Announcement: Moody's announces completion of a periodic review of ratings of Mylan N.V. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Mylan N.V. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
    Zacks5 days ago

    Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

    Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

  • Is MRK or GSK Expected to Report Faster Revenue Growth in 2019?
    Market Realist6 days ago

    Is MRK or GSK Expected to Report Faster Revenue Growth in 2019?

    MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY

  • Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
    Zacks6 days ago

    Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

    Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

  • Reuters8 days ago

    Mylan launches Advair generic at one-third price

    The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said. Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK. Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.

  • PR Newswire8 days ago

    Mylan Launches Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand

    HERTFORDSHIRE, England and PITTSBURGH, Feb. 12, 2019 /PRNewswire/ -- Mylan N.V. (MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ADVAIR DISKUS®, Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), approved by the U.S. Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) pathway. Wixela Inhub is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). All three strengths of Wixela Inhub will be offered at a wholesale acquisition cost* 70% less than ADVAIR DISKUS and 67% less than GSK's authorized generic version which launched on Feb. 8.

  • Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019
    PR Newswire9 days ago

    Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019

    HERTFORDSHIRE, England , and PITTSBURGH , Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 ...

  • Goldman Sachs pulls plug on 2-year-old, market-beating recommendation
    Yahoo Finance9 days ago

    Goldman Sachs pulls plug on 2-year-old, market-beating recommendation

    Goldman Sachs sees a dimmer outlook for stocks with strong balance sheets.

  • Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
    Zacks12 days ago

    Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

    While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

  • Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
    Reuters12 days ago

    Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

    The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. More than 763,000 tablets of the drug Amvalo, manufactured from April to July in Mylan Laboratories Limited in India, are the subject of recall, Pfizer Japan Inc said in a statement, adding there were no reports of any damage to health. "We will fully pay careful attention to our manufacturing and quality control to prevent a recurrence," Pfizer Japan President Akihisa Harada said.

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    Mylan NV NASDAQ/NGS:MYLView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MYL totaled $17.51 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Biogen's 'Battle-Tested' MS Drug Could Win Another Patent Dispute
    Investor's Business Daily13 days ago

    Why Biogen's 'Battle-Tested' MS Drug Could Win Another Patent Dispute

    Biogen will likely prevail in a patent challenge from Mylan for its multiple sclerosis treatment Tecfidera, several analysts said this week, though Biogen stock stumbled in Thursday trades.

  • 5 Undervalued Stocks to Invest In
    InvestorPlace13 days ago

    5 Undervalued Stocks to Invest In

    Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop when markets entered bear market territory. But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have had this luxury. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy … it has just become a little trickier to find them amid all the flashy comeback stories.To find the best stocks to invest in now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?InvestorPlace - Stock Market News, Stock Advice & Trading TipsMarkets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 10 Monster Growth Stocks to Buy for 2019 and Beyond With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem.Source: Dalvenjah via Flickr Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46.29 appears overdone. At just 4% above its yearly lows and a whopping 24% below its 52-week high, which SNE set just a few months ago, Sony stock clearly deserves its spot among the best undervalued stocks to consider now.Source: Shutterstock Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Semiconductor Stocks to Watch After falling 16% in the last week, Celestica stock is an undervalued play worth considering.Source: Everjean via Flickr Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) recently fell 12.8% for two reasons. First, its fourth-quarter earnings report did not please investors. Earnings-per-share came in at $4.29 (non-GAAP) while revenue fell 5.8% to $4.08 billion. With GAAP down $12.83 a share, its big difference from non-GAAP is scaring off investors. Allergan's accounting does not show any transparency in the health of the business.On Friday, Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for iinvestors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch.Source: Shutterstock Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose 17.5% weekly drop appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.6, the price-earnings-to-growth ratio is 0.55. As such, this general pessimism has created an appealing entry point to INVA stock. * 10 Dividend Growth Stocks You Can't Miss Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now.Source: Shutterstock Vodafone (VOD)Telecom stocks are out of favor. Just look at Verizon (NYSE:VZ), which is down 12% from its yearly highs; AT&T (NYSE:T) is down 24% from its highs. But Vodafone (NASDAQ: VOD) is down the most, falling 43% from its 52-week highs.Third-quarter results for VOD missed analyst consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. This is higher than Verizon's 4.45% dividend yield but almost a point below AT&T's 6.8% rate. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.

  • Barrons.com13 days ago

    Biogen Stock Slips on a Setback in a Patent Dispute With Mylan

    Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday.

  • Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
    Zacks13 days ago

    Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

    Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

  • A War on High Drug Prices Could Boost Biosimilars
    Motley Fool17 days ago

    A War on High Drug Prices Could Boost Biosimilars

    Putting an end to drug rebates to insurers could kick-start the use of low-cost biosimilar medications.

  • Mylan's Generic Version of Advair Diskus Wins FDA Approval
    Zacks19 days ago

    Mylan's Generic Version of Advair Diskus Wins FDA Approval

    Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

  • J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
    Zacks20 days ago

    J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

    Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

  • 6 Poorly Performing Stocks in Gurus' Portfolios
    GuruFocus.com20 days ago

    6 Poorly Performing Stocks in Gurus' Portfolios

    The pharmaceutical company has a $15 billion market cap. The stock is trading with a price-earnings ratio of 29.40. The return on equity of 4.26% and return on assets of 1.57% are underperforming 57% of companies in the Global Drug Manufacturers - Specialty & Generic industry.

  • Moody's20 days ago

    Mylan N.V. -- Moody's says FDA approval of generic Advair is credit positive for Mylan

    Moody's Investors Service commented that the Food & Drug Administration's (FDA) approval of Mylan N.V.'s ("Mylan", Baa3 stable) generic version of blockbuster drug Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is credit positive. Mylan's approval is the first generic of Advair. The approval is credit positive for Mylan because we believe it will be a good addition to earnings and cash flow in 2019 that will help support deleveraging.